Core Viewpoint - The article highlights the increasing sophistication of fraudulent businesses that disguise scams under the guise of "new consumption" and "new technology," exploiting regulatory gray areas and consumer trust [2][3]. Group 1: Consumer Fraud Trends - In 2026, consumer spending contributed 52% to economic growth, with total retail sales exceeding 50 trillion yuan, yet fraudulent practices continue to erode consumer trust [2]. - The 315 Gala revealed various scams, including toxic chicken feet sold at 15 yuan for 500 grams, which violate industry cost norms and involve dangerous production practices [5][7]. - A complete black industrial chain is identified, where illegal production and sales persist despite over 6 million inspections annually, indicating a severe imbalance between illegal profits and penalties [7][8]. Group 2: Specific Scams and Techniques - The medical beauty and height-increasing scams exploit consumer anxieties, using misleading claims and unproven products to extract significant fees from vulnerable individuals [9][10]. - Private domain marketing has intensified the exploitation of consumer fears, with companies selling ordinary drugs at inflated prices by falsely branding them as advanced therapies [10]. - The use of AI for generating fake reviews and misleading product recommendations marks a new era of consumer fraud, where trust in AI is manipulated to create a closed loop of misinformation [12]. Group 3: Regulatory Challenges - Traditional industries are adapting to new regulations by exploiting loopholes, as seen in the electric bicycle rental sector, where vehicles exceed safety standards while being marketed as compliant [13]. - The article emphasizes the need for a comprehensive regulatory framework that addresses the entire production, distribution, and sales chain to effectively combat these fraudulent practices [8][14]. - The 315 Gala's enforcement actions are seen as temporary measures, with a call for ongoing regulatory vigilance rather than sporadic crackdowns [13][14].

3 月 1 6 日 ， 锦 波 生 物 也 发 布 声 明 称 ， 此 类 " 套 证 " 行 为 ， 不 仅 严 重 违 反 《 医 疗 器 械 监 督 管 理 条 例》，更将未经安全性验证的物质直接用于人体注射，同时，这种恶意套用合法产品注册证的 行为，严重扰乱市场秩序，损害了合规人源化胶原蛋白企业的声誉。 | 截图自锦波生物官方声明/截图自新氧平台 | | --- | 事实上，在政策层面，"外泌体"的监管框架仍在形成之中。去年（2 0 2 5年）6月，国家药监局 药品审评中心发布《细胞治疗产品注册与评价技术指导原则（征求意见稿）》，拟将外泌体所 属的细胞外囊泡纳入"先进治疗药物（ATMP）"体系。截至3 · 1 5 曝光前，该《指导原则》仍 在征求意见阶段，我国尚无任何外泌体药品获批上市。 监管尚未落地，市场却已经提前"狂奔"。 这场围绕外泌体的风波，其实折射出当下美妆与医美产业的一个更深层变化：随着"医疗美容 —生活美容"融合趋势加速，越来越多原本属于医学或生物科技领域的概念，被快速引入到消 费市场。从重组胶原蛋白到PDRN，再到外泌体，"医美技术叙事"正在成为功效护肤和医美营 销的重要来源。 但当技 ...